MAPS’ recent economic study revealed huge cost savings from MDMA-assisted therapy to treat PTSD. But that could be just the beginning of the savings.

Entheon Biomedical has received conditional approval from the CSE to commence public trading.

The European Parliament voted last week to raise industrial hemp THC limits from 0.2 percent to 0.3 percent, aligning them with most other programs including the U.S., Hemp Industry Daily reports.

Financial support for marijuana legalization, both medical and recreational, has grown significantly in 2020 compared to 2016.

MDMA-assisted psychotherapy for PTSD is estimated to produce cost savings of $103,200 per patient, over a 30-year treatment horizon.

The Marijuana Policy Project has long been a leader in funding cannabis reform at the state and federal levels, but the current election season demonstrates that MPP’s role is shifting in a significant way – toward a more collaborative position with industry trade associations and large MJ companies.

The U.S. Department of Agriculture has approved New Mexico’s hemp planwhich will take effect for growers licensed after October 31.

As the new rally in psychedelic stocks progresses, these four companies are currently setting the pace.

Voters in South Dakota are poised to approve two separate ballot measures next month that would legalize marijuana and allow patients to access medical cannabis.

The Montana Supreme Court has rejected a challenge by Wrong for Montana against the ballot initiative to legalize adult-use cannabis sales in the state, MTPR reports.